Equities research analysts at Credit Suisse hoisted their price objective on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $275.00 to $340.00 in a research note issued to investors on Wednesday, ARN reports. The firm currently has an “outperform” rating on the stock. Credit Suisse’s target price indicates a potential upside of 17.94% from the stock’s previous close.
REGN has been the subject of a number of other recent research reports. Analysts at Cowen and Company raised their price target on shares of Regeneron Pharmaceuticals from $216.00 to $225.00 in a research note to investors on Wednesday. They now have a “market perform” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $325.00 to $331.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Wednesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $280.25.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock on the open market in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $300.74, for a total value of $300,740.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 4.65% during mid-day trading on Wednesday, hitting $288.27. 1,119,224 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $136.13 and a 52 week high of $319.83. The stock has a 50-day moving average of $299.1 and a 200-day moving average of $262.8. The company has a market cap of $28.164 billion and a P/E ratio of 39.97.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $2.40 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter in the previous year, the company posted $1.89 earnings per share. The company’s revenue for the quarter was up 39.6% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $3.56 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.